Hepatitis C-related hepatocellular carcinoma in the era of new generation antivirals View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2017-03-14

AUTHORS

Thomas F. Baumert, Frank Jühling, Atsushi Ono, Yujin Hoshida

ABSTRACT

Hepatitis C virus infection is a major cause of hepatocellular carcinoma worldwide. Interferon has been the major antiviral treatment, yielding viral clearance in approximately half of patients. New direct-acting antivirals substantially improved the cure rate to above 90%. However, access to therapies remains limited due to the high costs and under-diagnosis of infection in specific subpopulations, e.g., baby boomers, inmates, and injection drug users, and therefore, hepatocellular carcinoma incidence is predicted to increase in the next decades even in high-resource countries. Moreover, cancer risk persists even after 10 years of viral cure, and thus a clinical strategy for its monitoring is urgently needed. Several risk-predictive host factors, e.g., advanced liver fibrosis, older age, accompanying metabolic diseases such as diabetes, persisting hepatic inflammation, and elevated alpha-fetoprotein, as well as viral factors, e.g., core protein variants and genotype 3, have been reported. Indeed, a molecular signature in the liver has been associated with cancer risk even after viral cure. Direct-acting antivirals may affect cancer development and recurrence, which needs to be determined in further investigation. More... »

PAGES

52

Identifiers

URI

http://scigraph.springernature.com/pub.10.1186/s12916-017-0815-7

DOI

http://dx.doi.org/10.1186/s12916-017-0815-7

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1083941586

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/28288626


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1108", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical Microbiology", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antiviral Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Carcinoma, Hepatocellular", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Hepacivirus", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Hepatitis C", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Interferons", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Liver Cirrhosis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Liver Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoplasm Recurrence, Local", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Institut Hospitalo-Universitaire, P\u00f4le H\u00e9patodigestif, Nouvel H\u00f4pital Civil, Strasbourg, France", 
          "id": "http://www.grid.ac/institutes/grid.413866.e", 
          "name": [
            "Inserm, U1110, Institut de Recherche sur les Maladies Virales et H\u00e9patiques, Strasbourg, France", 
            "Universit\u00e9 de Strasbourg, Strasbourg, France", 
            "Institut Hospitalo-Universitaire, P\u00f4le H\u00e9patodigestif, Nouvel H\u00f4pital Civil, Strasbourg, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Baumert", 
        "givenName": "Thomas F.", 
        "id": "sg:person.014465207621.91", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014465207621.91"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Universit\u00e9 de Strasbourg, Strasbourg, France", 
          "id": "http://www.grid.ac/institutes/grid.11843.3f", 
          "name": [
            "Inserm, U1110, Institut de Recherche sur les Maladies Virales et H\u00e9patiques, Strasbourg, France", 
            "Universit\u00e9 de Strasbourg, Strasbourg, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "J\u00fchling", 
        "givenName": "Frank", 
        "id": "sg:person.01022166750.31", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01022166750.31"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Gastroenterology and Metabolism, Applied Life Sciences, Institute of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan", 
          "id": "http://www.grid.ac/institutes/grid.257022.0", 
          "name": [
            "Division of Liver Diseases, Department of Medicine, Liver Cancer Program, Tisch Cancer Institute, Graduate School of Biomedical Sciences, Icahn School of Medicine at Mount Sinai, 1470 Madison Ave, Box 1123, 10029, New York, NY, USA", 
            "Department of Gastroenterology and Metabolism, Applied Life Sciences, Institute of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ono", 
        "givenName": "Atsushi", 
        "id": "sg:person.0755521730.32", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0755521730.32"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of Liver Diseases, Department of Medicine, Liver Cancer Program, Tisch Cancer Institute, Graduate School of Biomedical Sciences, Icahn School of Medicine at Mount Sinai, 1470 Madison Ave, Box 1123, 10029, New York, NY, USA", 
          "id": "http://www.grid.ac/institutes/grid.516104.7", 
          "name": [
            "Division of Liver Diseases, Department of Medicine, Liver Cancer Program, Tisch Cancer Institute, Graduate School of Biomedical Sciences, Icahn School of Medicine at Mount Sinai, 1470 Madison Ave, Box 1123, 10029, New York, NY, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hoshida", 
        "givenName": "Yujin", 
        "id": "sg:person.01001522721.19", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01001522721.19"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1038/nm.3184", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1043962611", 
          "https://doi.org/10.1038/nm.3184"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/1471-230x-14-137", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1021699719", 
          "https://doi.org/10.1186/1471-230x-14-137"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00535-013-0921-z", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012455091", 
          "https://doi.org/10.1007/s00535-013-0921-z"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00535-004-1519-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1035239618", 
          "https://doi.org/10.1007/s00535-004-1519-2"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2017-03-14", 
    "datePublishedReg": "2017-03-14", 
    "description": "Hepatitis C virus infection is a major cause of hepatocellular carcinoma worldwide. Interferon has been the major antiviral treatment, yielding viral clearance in approximately half of patients. New direct-acting antivirals substantially improved the cure rate to above 90%. However, access to therapies remains limited due to the high costs and under-diagnosis of infection in specific subpopulations, e.g., baby boomers, inmates, and injection drug users, and therefore, hepatocellular carcinoma incidence is predicted to increase in the next decades even in high-resource countries. Moreover, cancer risk persists even after 10\u00a0years of viral cure, and thus a clinical strategy for its monitoring is urgently needed. Several risk-predictive host factors, e.g., advanced liver fibrosis, older age, accompanying metabolic diseases such as diabetes, persisting hepatic inflammation, and elevated alpha-fetoprotein, as well as viral factors, e.g., core protein variants and genotype 3, have been reported. Indeed, a molecular signature in the liver has been associated with cancer risk even after viral cure. Direct-acting antivirals may affect cancer development and recurrence, which needs to be determined in further investigation.", 
    "genre": "article", 
    "id": "sg:pub.10.1186/s12916-017-0815-7", 
    "isAccessibleForFree": true, 
    "isFundedItemOf": [
      {
        "id": "sg:grant.2500917", 
        "type": "MonetaryGrant"
      }, 
      {
        "id": "sg:grant.4242914", 
        "type": "MonetaryGrant"
      }, 
      {
        "id": "sg:grant.5051108", 
        "type": "MonetaryGrant"
      }, 
      {
        "id": "sg:grant.4273932", 
        "type": "MonetaryGrant"
      }, 
      {
        "id": "sg:grant.7140250", 
        "type": "MonetaryGrant"
      }
    ], 
    "isPartOf": [
      {
        "id": "sg:journal.1032885", 
        "issn": [
          "1741-7015"
        ], 
        "name": "BMC Medicine", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "15"
      }
    ], 
    "keywords": [
      "viral cure", 
      "hepatocellular carcinoma", 
      "cancer risk", 
      "hepatitis C virus infection", 
      "C virus infection", 
      "half of patients", 
      "Direct-acting antivirals", 
      "advanced liver fibrosis", 
      "injection drug users", 
      "hepatocellular carcinoma incidence", 
      "diagnosis of infection", 
      "high-resource countries", 
      "hepatitis C", 
      "hepatic inflammation", 
      "antiviral treatment", 
      "viral clearance", 
      "carcinoma incidence", 
      "cure rate", 
      "liver fibrosis", 
      "genotype 3", 
      "virus infection", 
      "clinical strategies", 
      "metabolic diseases", 
      "drug users", 
      "alpha-fetoprotein", 
      "viral factors", 
      "older age", 
      "cancer development", 
      "specific subpopulations", 
      "host factors", 
      "major cause", 
      "antivirals", 
      "core protein variants", 
      "carcinoma", 
      "infection", 
      "molecular signatures", 
      "further investigation", 
      "cure", 
      "risk", 
      "patients", 
      "diabetes", 
      "inflammation", 
      "recurrence", 
      "fibrosis", 
      "interferon", 
      "therapy", 
      "incidence", 
      "disease", 
      "diagnosis", 
      "liver", 
      "clearance", 
      "age", 
      "treatment", 
      "factors", 
      "subpopulations", 
      "cause", 
      "baby boomers", 
      "years", 
      "high cost", 
      "half", 
      "variants", 
      "inmates", 
      "next decade", 
      "protein variants", 
      "rate", 
      "monitoring", 
      "access", 
      "strategies", 
      "development", 
      "boomers", 
      "countries", 
      "investigation", 
      "decades", 
      "era", 
      "signatures", 
      "cost", 
      "users"
    ], 
    "name": "Hepatitis C-related hepatocellular carcinoma in the era of new generation antivirals", 
    "pagination": "52", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1083941586"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1186/s12916-017-0815-7"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "28288626"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1186/s12916-017-0815-7", 
      "https://app.dimensions.ai/details/publication/pub.1083941586"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-12-01T06:35", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221201/entities/gbq_results/article/article_727.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1186/s12916-017-0815-7"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/s12916-017-0815-7'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/s12916-017-0815-7'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/s12916-017-0815-7'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/s12916-017-0815-7'


 

This table displays all metadata directly associated to this object as RDF triples.

237 TRIPLES      21 PREDICATES      116 URIs      103 LITERALS      16 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1186/s12916-017-0815-7 schema:about N61d3de414dfb42ba88dc5d58639240a7
2 N7e93f95b0c6b45e9b6e6dd47eda1907b
3 N856bceb486284766ac349ffee058a824
4 N85f72c71fc6c4f31ad9838b6e7284248
5 N8e1fc9a7ae474a2bbd99d7e53e7626c7
6 N9a69758a612d4ba98cbe0a91f1560eb0
7 Nc4466e896a9f417bac6e5aea291f125c
8 Nd8f360b5778d4c6fb022ea95812a4ad1
9 Nff924895c8c4488985961f1b35bb6980
10 anzsrc-for:11
11 anzsrc-for:1108
12 anzsrc-for:1112
13 schema:author Nae860b10709d4806af505d154f342f56
14 schema:citation sg:pub.10.1007/s00535-004-1519-2
15 sg:pub.10.1007/s00535-013-0921-z
16 sg:pub.10.1038/nm.3184
17 sg:pub.10.1186/1471-230x-14-137
18 schema:datePublished 2017-03-14
19 schema:datePublishedReg 2017-03-14
20 schema:description Hepatitis C virus infection is a major cause of hepatocellular carcinoma worldwide. Interferon has been the major antiviral treatment, yielding viral clearance in approximately half of patients. New direct-acting antivirals substantially improved the cure rate to above 90%. However, access to therapies remains limited due to the high costs and under-diagnosis of infection in specific subpopulations, e.g., baby boomers, inmates, and injection drug users, and therefore, hepatocellular carcinoma incidence is predicted to increase in the next decades even in high-resource countries. Moreover, cancer risk persists even after 10 years of viral cure, and thus a clinical strategy for its monitoring is urgently needed. Several risk-predictive host factors, e.g., advanced liver fibrosis, older age, accompanying metabolic diseases such as diabetes, persisting hepatic inflammation, and elevated alpha-fetoprotein, as well as viral factors, e.g., core protein variants and genotype 3, have been reported. Indeed, a molecular signature in the liver has been associated with cancer risk even after viral cure. Direct-acting antivirals may affect cancer development and recurrence, which needs to be determined in further investigation.
21 schema:genre article
22 schema:isAccessibleForFree true
23 schema:isPartOf N43b3a21dede14bd8b9cea8a01666fd96
24 N711405bcda5b47cf81e0805c5333cf87
25 sg:journal.1032885
26 schema:keywords C virus infection
27 Direct-acting antivirals
28 access
29 advanced liver fibrosis
30 age
31 alpha-fetoprotein
32 antiviral treatment
33 antivirals
34 baby boomers
35 boomers
36 cancer development
37 cancer risk
38 carcinoma
39 carcinoma incidence
40 cause
41 clearance
42 clinical strategies
43 core protein variants
44 cost
45 countries
46 cure
47 cure rate
48 decades
49 development
50 diabetes
51 diagnosis
52 diagnosis of infection
53 disease
54 drug users
55 era
56 factors
57 fibrosis
58 further investigation
59 genotype 3
60 half
61 half of patients
62 hepatic inflammation
63 hepatitis C
64 hepatitis C virus infection
65 hepatocellular carcinoma
66 hepatocellular carcinoma incidence
67 high cost
68 high-resource countries
69 host factors
70 incidence
71 infection
72 inflammation
73 injection drug users
74 inmates
75 interferon
76 investigation
77 liver
78 liver fibrosis
79 major cause
80 metabolic diseases
81 molecular signatures
82 monitoring
83 next decade
84 older age
85 patients
86 protein variants
87 rate
88 recurrence
89 risk
90 signatures
91 specific subpopulations
92 strategies
93 subpopulations
94 therapy
95 treatment
96 users
97 variants
98 viral clearance
99 viral cure
100 viral factors
101 virus infection
102 years
103 schema:name Hepatitis C-related hepatocellular carcinoma in the era of new generation antivirals
104 schema:pagination 52
105 schema:productId N52285199224b48bc82aa0f57b567557c
106 N6c7a8894f9e54665a6b9761644af4783
107 N732e6aa897364990bb99e4f2586f4faf
108 schema:sameAs https://app.dimensions.ai/details/publication/pub.1083941586
109 https://doi.org/10.1186/s12916-017-0815-7
110 schema:sdDatePublished 2022-12-01T06:35
111 schema:sdLicense https://scigraph.springernature.com/explorer/license/
112 schema:sdPublisher Nbd592a40b41040df83ea0e47e3216193
113 schema:url https://doi.org/10.1186/s12916-017-0815-7
114 sgo:license sg:explorer/license/
115 sgo:sdDataset articles
116 rdf:type schema:ScholarlyArticle
117 N1054b9aebae249ad8eadc04ceb9d0994 rdf:first sg:person.01022166750.31
118 rdf:rest Nc7bd203090e8472c9cc563961533a8e2
119 N43b3a21dede14bd8b9cea8a01666fd96 schema:volumeNumber 15
120 rdf:type schema:PublicationVolume
121 N52285199224b48bc82aa0f57b567557c schema:name doi
122 schema:value 10.1186/s12916-017-0815-7
123 rdf:type schema:PropertyValue
124 N61d3de414dfb42ba88dc5d58639240a7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
125 schema:name Liver Neoplasms
126 rdf:type schema:DefinedTerm
127 N6c7a8894f9e54665a6b9761644af4783 schema:name dimensions_id
128 schema:value pub.1083941586
129 rdf:type schema:PropertyValue
130 N711405bcda5b47cf81e0805c5333cf87 schema:issueNumber 1
131 rdf:type schema:PublicationIssue
132 N732e6aa897364990bb99e4f2586f4faf schema:name pubmed_id
133 schema:value 28288626
134 rdf:type schema:PropertyValue
135 N7e93f95b0c6b45e9b6e6dd47eda1907b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
136 schema:name Humans
137 rdf:type schema:DefinedTerm
138 N856bceb486284766ac349ffee058a824 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
139 schema:name Hepacivirus
140 rdf:type schema:DefinedTerm
141 N85f72c71fc6c4f31ad9838b6e7284248 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
142 schema:name Interferons
143 rdf:type schema:DefinedTerm
144 N8e1fc9a7ae474a2bbd99d7e53e7626c7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
145 schema:name Antiviral Agents
146 rdf:type schema:DefinedTerm
147 N9a69758a612d4ba98cbe0a91f1560eb0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
148 schema:name Carcinoma, Hepatocellular
149 rdf:type schema:DefinedTerm
150 Nae860b10709d4806af505d154f342f56 rdf:first sg:person.014465207621.91
151 rdf:rest N1054b9aebae249ad8eadc04ceb9d0994
152 Nbd592a40b41040df83ea0e47e3216193 schema:name Springer Nature - SN SciGraph project
153 rdf:type schema:Organization
154 Nc4466e896a9f417bac6e5aea291f125c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
155 schema:name Hepatitis C
156 rdf:type schema:DefinedTerm
157 Nc7bd203090e8472c9cc563961533a8e2 rdf:first sg:person.0755521730.32
158 rdf:rest Ne7d5550cd4b149a9b5bc1fd8ec124103
159 Nd8f360b5778d4c6fb022ea95812a4ad1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
160 schema:name Neoplasm Recurrence, Local
161 rdf:type schema:DefinedTerm
162 Ne7d5550cd4b149a9b5bc1fd8ec124103 rdf:first sg:person.01001522721.19
163 rdf:rest rdf:nil
164 Nff924895c8c4488985961f1b35bb6980 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
165 schema:name Liver Cirrhosis
166 rdf:type schema:DefinedTerm
167 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
168 schema:name Medical and Health Sciences
169 rdf:type schema:DefinedTerm
170 anzsrc-for:1108 schema:inDefinedTermSet anzsrc-for:
171 schema:name Medical Microbiology
172 rdf:type schema:DefinedTerm
173 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
174 schema:name Oncology and Carcinogenesis
175 rdf:type schema:DefinedTerm
176 sg:grant.2500917 http://pending.schema.org/fundedItem sg:pub.10.1186/s12916-017-0815-7
177 rdf:type schema:MonetaryGrant
178 sg:grant.4242914 http://pending.schema.org/fundedItem sg:pub.10.1186/s12916-017-0815-7
179 rdf:type schema:MonetaryGrant
180 sg:grant.4273932 http://pending.schema.org/fundedItem sg:pub.10.1186/s12916-017-0815-7
181 rdf:type schema:MonetaryGrant
182 sg:grant.5051108 http://pending.schema.org/fundedItem sg:pub.10.1186/s12916-017-0815-7
183 rdf:type schema:MonetaryGrant
184 sg:grant.7140250 http://pending.schema.org/fundedItem sg:pub.10.1186/s12916-017-0815-7
185 rdf:type schema:MonetaryGrant
186 sg:journal.1032885 schema:issn 1741-7015
187 schema:name BMC Medicine
188 schema:publisher Springer Nature
189 rdf:type schema:Periodical
190 sg:person.01001522721.19 schema:affiliation grid-institutes:grid.516104.7
191 schema:familyName Hoshida
192 schema:givenName Yujin
193 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01001522721.19
194 rdf:type schema:Person
195 sg:person.01022166750.31 schema:affiliation grid-institutes:grid.11843.3f
196 schema:familyName Jühling
197 schema:givenName Frank
198 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01022166750.31
199 rdf:type schema:Person
200 sg:person.014465207621.91 schema:affiliation grid-institutes:grid.413866.e
201 schema:familyName Baumert
202 schema:givenName Thomas F.
203 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014465207621.91
204 rdf:type schema:Person
205 sg:person.0755521730.32 schema:affiliation grid-institutes:grid.257022.0
206 schema:familyName Ono
207 schema:givenName Atsushi
208 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0755521730.32
209 rdf:type schema:Person
210 sg:pub.10.1007/s00535-004-1519-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1035239618
211 https://doi.org/10.1007/s00535-004-1519-2
212 rdf:type schema:CreativeWork
213 sg:pub.10.1007/s00535-013-0921-z schema:sameAs https://app.dimensions.ai/details/publication/pub.1012455091
214 https://doi.org/10.1007/s00535-013-0921-z
215 rdf:type schema:CreativeWork
216 sg:pub.10.1038/nm.3184 schema:sameAs https://app.dimensions.ai/details/publication/pub.1043962611
217 https://doi.org/10.1038/nm.3184
218 rdf:type schema:CreativeWork
219 sg:pub.10.1186/1471-230x-14-137 schema:sameAs https://app.dimensions.ai/details/publication/pub.1021699719
220 https://doi.org/10.1186/1471-230x-14-137
221 rdf:type schema:CreativeWork
222 grid-institutes:grid.11843.3f schema:alternateName Université de Strasbourg, Strasbourg, France
223 schema:name Inserm, U1110, Institut de Recherche sur les Maladies Virales et Hépatiques, Strasbourg, France
224 Université de Strasbourg, Strasbourg, France
225 rdf:type schema:Organization
226 grid-institutes:grid.257022.0 schema:alternateName Department of Gastroenterology and Metabolism, Applied Life Sciences, Institute of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan
227 schema:name Department of Gastroenterology and Metabolism, Applied Life Sciences, Institute of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan
228 Division of Liver Diseases, Department of Medicine, Liver Cancer Program, Tisch Cancer Institute, Graduate School of Biomedical Sciences, Icahn School of Medicine at Mount Sinai, 1470 Madison Ave, Box 1123, 10029, New York, NY, USA
229 rdf:type schema:Organization
230 grid-institutes:grid.413866.e schema:alternateName Institut Hospitalo-Universitaire, Pôle Hépatodigestif, Nouvel Hôpital Civil, Strasbourg, France
231 schema:name Inserm, U1110, Institut de Recherche sur les Maladies Virales et Hépatiques, Strasbourg, France
232 Institut Hospitalo-Universitaire, Pôle Hépatodigestif, Nouvel Hôpital Civil, Strasbourg, France
233 Université de Strasbourg, Strasbourg, France
234 rdf:type schema:Organization
235 grid-institutes:grid.516104.7 schema:alternateName Division of Liver Diseases, Department of Medicine, Liver Cancer Program, Tisch Cancer Institute, Graduate School of Biomedical Sciences, Icahn School of Medicine at Mount Sinai, 1470 Madison Ave, Box 1123, 10029, New York, NY, USA
236 schema:name Division of Liver Diseases, Department of Medicine, Liver Cancer Program, Tisch Cancer Institute, Graduate School of Biomedical Sciences, Icahn School of Medicine at Mount Sinai, 1470 Madison Ave, Box 1123, 10029, New York, NY, USA
237 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...